Abstract
The global response to the SARS-Cov-2 pandemic has consisted of two main strategies both involving non-pharmaceutical interventions to control spread: mitigation, ultimately relying on herd immunity from vaccination, and elimination of infections locally. While simple theory for controlling an epidemic through herd immunity exist, there is no corresponding simple theory for the strategy of elimination with non-pharmaceutical interventions. Here we quantify an important aspect of the elimination strategy: the time to extinction without herd immunity, based solely on non-pharmaceutical interventions. Using a simple well-mixed stochastic SIR model, we find two new results: 1) using random walk theory we calculate a simple approximation of the mean extinction time and 2) using branching process theory the full distribution of times to extinction, which we show is given by the extreme value Gumbel distribution. We compare these results against complex spatially-resolved stochastic simulations to show very good quantitative agreement, demonstrating the validity of this simple approach. Overall, for SARS-Cov-2 our results predict rapid extinction — of order months — of an epidemic or pandemic if the reproductive number is kept to Re < 0.5; in a counterfactual scenario with global adoption of an elimination strategy in June 2020, SARS-Cov-2 could have been eliminated world-wide by early January 2021.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.